Wendy L. Dixon - Apr 25, 2023 Form 4 Insider Report for ZEVRA THERAPEUTICS, INC. (ZVRA)

Role
Director
Signature
/s/ Timothy J. Sangiovanni, Attorney-in-Fact for Wendy L. Dixon
Stock symbol
ZVRA
Transactions as of
Apr 25, 2023
Transactions value $
$0
Form type
4
Date filed
5/8/2023, 09:50 PM
Previous filing
Mar 20, 2023
Next filing
May 17, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZVRA Stock Option (right to buy) Award $0 +22.5K $0.00 22.5K Apr 25, 2023 Common Stock 22.5K $5.59 Direct F1, F2, F3
transaction ZVRA Stock Option (right to buy) Award $0 +36.3K $0.00 36.3K May 3, 2023 Common Stock 36.3K $4.97 Direct F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, April 25, 2023.
F2 This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors.
F3 33.33% of the total shares subject to the option vest in equal annual installments beginning one day prior to the date of the first annual meeting of the Issuer's stockholders following the day of grant and continuing for the next two annual meeting of the Issuer's stockholders, such that the option will be fully vested one day prior to the date of the third annual meeting of the Issuer's stockholders following the day of the grant, provided that at the relevant vesting dates such optionee's directorial relationship has not been terminated as defined in and as determined under the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer.
F4 The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, May 3, 2023.
F5 This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's ninth amended and restated non-employee director compensation policy.